Abstract
The metabolic syndrome is defined by the concurrent presence of at least three metabolic disorders that are associated with an increased risk of cardiovascular disease and diabetes. Results from prospective and cross-sectional studies also point to an association between the metabolic syndrome and chronic kidney disease. Visceral obesity and insulin resistance are two important features of the metabolic syndrome that might explain renal injury. We reviewed the literature to examine whether treatment of the metabolic syndrome can favorably influence renal outcomes. Weight loss, regular exercise, and a low-calorie, low-fat diet are first-line treatments of the metabolic syndrome, yet few data are available to indicate that such lifestyle interventions can prevent or reverse renal damage. Similarly, results from few studies show little or no beneficial effect of blood pressure control, use of statins, fibrates, thiazolidinediones or metformin on renal parameters in patients with metabolic syndrome. The reasons for the lack of trials in this research field are also discussed. This Review identifies the need to improve understanding of the role of metabolic syndrome in chronic kidney disease, define consistent criteria for metabolic syndrome and perform clinical trials that analyze renal outcomes as primary end points.
Key Points
-
The metabolic syndrome is a constellation of metabolic risk factors that predict increased risks of cardiovascular disease and diabetes
-
In cross-sectional and longitudinal studies, the metabolic syndrome is associated with chronic kidney disease and microalbuminuria
-
Abdominal obesity and insulin resistance are widely considered to be key mechanisms of metabolic-syndrome-mediated renal damage
-
Limited studies demonstrate that treatment of the metabolic syndrome by way of lifestyle changes, pharmacotherapies, or both, can improve markers of renal function
-
Increased recognition of the metabolic syndrome and early intervention for this condition could improve cardiovascular and renal outcomes
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2005).
Scott, M. et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433–438 (2004).
Kitiyakara, C. et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int. 71, 693–700 (2007).
Luk, A. O. et al. The NCEP-ATPIII but not the IDF criteria for the metabolic syndrome identify type 2 diabetic patients at increased risk of chronic kidney disease. Diabet. Med. 25, 1419–1425 (2008).
Ford, E. S., Giles, W. H. & Mokdad, A. H. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27, 2444–2449 (2004).
Ford, E. S., Giles, W. H. & Dietz, W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356–359 (2002).
Kahn, R. et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 289, 2289–2304 (2005).
Kurella, M., Lo, J. C. & Chertow, G. M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J. Am. Soc. Nephrol. 16, 2134–2140 (2005).
Fox, C. S. et al. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 28, 2436–2440 (2005).
Bonnet, F. et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J. Hypertens. 24, 1157–1163 (2006).
Ryu, S. et al. Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am. J. Kidney Dis. 53, 59–69 (2009).
Lea, J. et al. Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am. J. Kidney Dis. 51, 732–740 (2008).
Tozawa, M. et al. Metabolic syndrome and risk of developing chronic kidney disease in japanese adults. Hypertens. Res. 30, 937–943 (2007).
Kitiyakara, C. et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int. 71, 693–700 (2007).
Lucove, J., Vupputuri, S., Heiss, G., North, K. & Russell, M. Metabolic Syndrome and the development of CKD in American Indians: The Strong Heart Study. Am. J. Kidney Dis. 51, 21–28 (2008).
Luk, A. O. et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5 829 patients with type 2 diabetes. Diabetes Care 31, 2357–2361 (2008).
Ninomiya, T. et al. Metabolic syndrome and CKD in a general Japanese population: The Hisayama Study. Am. J. Kidney Dis. 48, 383–391 (2006).
Rashidi, A., Ghanbarian, A. & Azizi, F. Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin. J. Am. Soc. Nephrol. 2, 976–983 (2007).
Chen, J. et al. The metabolic syndrome and chronic kidney disease in US adults. Ann. Intern. Med. 140, 167–174 (2004).
Peralta, C. A., Kurella, M., Lo, J. C. & Chertow, G. M. The metabolic syndrome and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 15, 361–365 (2006).
Bagby, S. P. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J. Am. Soc. Nephrol. 15, 2775–2791 (2004).
Wahba, I. M. & Mak, R. H. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2, 550–562 (2007).
Alberti, K. G., Zimmet, P., Shaw, J. & IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet 366, 1059–1062 (2005).
Wajchenberg, B. L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 21, 697–738 (2000).
Elsayed, E. F. et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am. J. Kidney Dis. 52, 29–38 (2008).
Wellen, K. E. & Hotamisligil, G. S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112, 1785–1788 (2003).
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E. & Klein, S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56, 1010–1013 (2007).
Wisse, B. E. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15, 2792–2800 (2004).
Freedland, E. S. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr. Metab. (Lond.) 1, 12 (2004).
Weinberg, J. M. Lipotoxicity. Kidney Int. 70, 1560–1566 (2006).
Nishida, Y., Oda, H. & Yorioka, N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int. 56, S51–S53 (1999).
Walker, W. G. Relation of lipid abnormalities to progression of renal damage in essential hypertension, insulin-dependent and non insulin-dependent diabetes mellitus. Miner. Electrolyte Metab. 19, 137–143 (1993).
Martin, S. S., Qasim, A. & Reilly, M. P. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J. Am. Coll. Cardiol. 52, 1201–1210 (2008).
Arita, Y. et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79–83 (1999).
Shulman, G. I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171–176 (2000).
Sarafidis, P. A. & Ruilope, L. M. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am. J. Nephrol. 26, 232–244 (2006).
Cooper, M. E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352, 213–219 (1998).
DeFronzo, R. A., Cooke, C. R., Andres, R., Faloona, G. R. & Davis, P. J. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J. Clin. Invest. 55, 845–855 (1975).
Rowe, J. W. et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30, 219–225 (1981).
Miller, A. W., Hoenig, M. E. & Ujhelyi, M. R. Mechanisms of impaired endothelial function associated with insulin resistance. J. Cardiovasc. Pharmacol. Ther. 3, 125–134 (1998).
Peterson, J. C. et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med. 123, 754–762 (1995).
Dengel, D. R., Goldberg, A. P., Mayuga, R. S., Kairis, G. M. & Weir, M. R. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension 28, 127–132 (1996).
Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J. & D'Agati, V. D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59, 1498–1509 (2001).
Alexander, M. P. et al. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am. J. Kidney Dis. 53, 751–759 (2009).
Strippoli, G. F., Craig, J. C. & Schena, F. P. The number, quality, and coverage of randomized controlled trials in nephrology. J. Am. Soc. Nephrol. 15, 411–419 (2004).
Scott, M. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation 112, e285–e290 (2005).
Bestermann, W. et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am. J. Med. Sci. 329, 292–305 (2005).
Gaede, P., Vedel, P., Parving, H. H. & Pedersen, O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353, 617–622 (1999).
Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837–1847 (1998).
Hayden, M. R. et al. Detecting microalbuminuria and taking action in the cardiometabolic syndrome and type 2 diabetes mellitus. Mo. Med. 103, 533–538 (2006).
Balkau, B. et al. The impact of 3-year changes in lifestyle habits on metabolic syndrome parameters: the D. E. S. I. R study. Eur. J. Cardiovasc. Prev. Rehabil. 13, 334–340 (2006).
Tjønna, A. E. et al. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. Circulation 118, 346–354 (2008).
Thompson, P. D. et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107, 3109–3116 (2003).
Finkelstein, J., Joshi, A. & Hise, M. K. Association of physical activity and renal function in subjects with and without metabolic syndrome: a review of the Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 48, 372–382 (2006).
Fredrickson, S. K., Ferro, T. J. & Schutrumpf, A. C. Disappearance of microalbuminuria in a patient with type 2 diabetes and the metabolic syndrome in the setting of an intense exercise and dietary program with sustained weight reduction. Diabetes Care 27, 1754–1755 (2004).
Hong, K., Li, Z., Wang, H. J., Elashoff, R. & Heber, D. Analysis of weight loss outcomes using VLCD in black and white overweight and obese women with and without metabolic syndrome. Int. J. Obes. (Lond.) 29, 436–442 (2005).
Meckling, K. A. & Sherfey, R. A randomized trial of a hypocaloric high-protein diet, with and without exercise, on weight loss, fitness, and markers of the Metabolic Syndrome in overweight and obese women. Appl. Physiol. Nutr. Metab. 32, 743–752 (2007).
Straznicky, N. E. et al. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J. Clin. Endocrinol. Metab. 90, 5998–6005 (2005).
Kushner, R. F. & Doerfler, B. Low-carbohydrate, high-protein diets revisited. Curr. Opin. Gastroenterol. 24, 198–203 (2008).
Friedman, A. N. High-protein diets: potential effects on the kidney in renal health and disease. Am. J. Kidney Dis. 44, 950–962 (2004).
Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P. & Schaefer, E. J. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293, 43–53 (2005).
Zanella, M. T. et al. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study. Arq. Bras. Endocrinol. Metabol. 50, 368–376 (2006).
Reaven, G., Segal, K., Hauptman, J., Boldrin, M. & Lucas, C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am. J. Cardiol. 87, 827–831 (2001).
Filippatos, T. D. et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr. Med. Res. Opin. 21, 1997–2006 (2005).
Broeders, N., Knoop, C., Antoine, M., Tielemans, C. & Abramowicz, D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol. Dial. Transplant. 15, 1993–1999 (2000).
Courtney, A. E., O'Rourke, D. M. & Maxwell, A. P. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol. Dial. Transplant. 22, 621–623 (2007).
Krejs, G. J. Metabolic benefits associated with sibutramine therapy. Int. J. Obes. Relat. Metab. Disord. 26 (Suppl. 4), S34–S37 (2002).
Kushner, R. F. Medical management of obesity. Semin. Gastrointest. Dis. 13, 123–132 (2002).
Lindholm, A. et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil. Steril. 89, 1221–1228 (2008).
Van Gaal, L. F. et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur. Heart J. 29, 1761–1771 (2008).
Batsis, J. A. et al. Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin. Proc. 83, 897–907 (2008).
Chagnac, A. et al. The effects of weight loss on renal function in patients with severe obesity. J. Am. Soc. Nephrol. 14, 1480–1486 (2003).
Agrawal, V. et al. The effect of weight loss after bariatric surgery on albuminuria. Clin. Nephrol. 70, 194–202 (2008).
Nelson, W. K., Houghton, S. G., Milliner, D. S., Lieske, J. C. & Sarr, M. G. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg. Obes. Relat. Dis. 1, 481–485 (2005).
Chen, J. & Townsend, R. R. Preventing cardiovascular and renal complications in the management of hypertension and metabolic syndrome. Expert. Opin. Pharmacother. 8, 2001–2009 (2007).
Orchard, T. J. et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142, 611–619 (2005).
Ford, E. S. Rarer than a blue moon: the use of a diagnostic code for the metabolic syndrome in the US Diabetes Care 28, 1808–1809 (2005).
Reynolds, K., Muntner, P. & Fonseca, V. Metabolic syndrome: underrated or underdiagnosed? Diabetes Care 28, 1831–1832 (2005).
Kincaid-Smith, P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'. J. Hypertens. 22, 1051–1055 (2004).
Xie, D. et al. A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 1332–1338 (2008).
Navarro-Díaz, M. et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J. Am. Soc. Nephrol. 17 (Suppl. 3), S213–S217 (2006).
Black, H. R. et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Diabetes Care 31, 353–360 (2008).
Uzu, T. et al. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome. Hypertens. Res. 30, 161–165 (2007).
Chobanian, A. V. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206–1252 (2003).
Segura, J. et al. Should hypertension guidelines be changed for hypertensive patients with the metabolic syndrome? J. Clin. Hypertens. (Greenwich) 9, 595–600 (2007).
Ruan, X., Zheng, F. & Guan, Y. PPARs and the kidney in metabolic syndrome. Am. J. Physiol. Renal Physiol. 294, F1032–F1047 (2008).
Sarafidis, P. A. & Bakris, G. L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 70, 1223–1233 (2006).
Lee, T. M., Su, S. F. & Tsai, C. H. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40, 67–73 (2002).
Athyros, V. G. et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol. Dial. Transplant. 22, 118–127 (2007).
Vitale, C. et al. Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. 258, 250–256 (2005).
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am. J. Kidney Dis. 41 (Suppl. 3), S1–S91 (2003).
Diabetes Prevention Program Research Group. Changes in albumin excretion in the diabetes prevention program. Diabetes Care 32, 720–725 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Agrawal, V., Shah, A., Rice, C. et al. Impact of treating the metabolic syndrome on chronic kidney disease. Nat Rev Nephrol 5, 520–528 (2009). https://doi.org/10.1038/nrneph.2009.114
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.114
This article is cited by
-
Prevalence and risk factors of kidney stone disease in population aged 40–70 years old in Kharameh cohort study: a cross-sectional population-based study in southern Iran
BMC Urology (2022)
-
Metabolic Syndrome Rather than Obesity Alone Is More Significant for Kidney Disease
Obesity Surgery (2019)
-
Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms
Laboratory Investigation (2018)
-
Renal outcomes of bariatric surgery in obese adults with diabetic kidney disease
Journal of Nephrology (2014)
-
A discovery-phase urine proteomics investigation in type 1 diabetes
Acta Diabetologica (2012)